{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:56:25Z","timestamp":1786755385975,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T00:00:00Z","timestamp":1705708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T00:00:00Z","timestamp":1705708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To review available and emerging evidence of radiotherapy for symptom management and disease control in metastatic bladder cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A literature search and subsequent cross-referencing were carried out for articles in the PubMed and Scopus databases using terms \u2018radiotherapy\u2019 OR \u2018palliative radiation therapy\u2019 with \u2018metastatic bladder cancer\u2019 OR \u2018advanced bladder cancer\u2019 between 1990 and 2023, excluding articles with no English translation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Palliative radiotherapy is an effective and accessible treatment for the alleviation of haematuria and pain due to the primary and metastatic disease. With growing recognition of oligometastatic disease state at diagnosis, response, or progression, radiotherapy can consolidate response by ablating residual or resistant lesions. Experience with other primary cancers supports positive impact of radiotherapy on disease control, quality of life, and survival in oligometastatic stage, without significant adverse effects. Alongside immune checkpoint inhibitors, fibroblast growth receptor inhibitors, and antibody\u2013drug conjugates, the immunomodulatory potential of radiotherapy is being explored in combination with these systemic therapies for metastatic bladder cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Radiotherapy is an effective, safe, and accessible treatment modality for palliation as well as disease control in various clinical settings of metastatic bladder cancer. Its role in oligometastatic stage in combination with systemic therapy is expected to expand with emerging evidence.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00345-023-04744-x","type":"journal-article","created":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T10:02:28Z","timestamp":1705744948000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Radiotherapy in metastatic bladder cancer"],"prefix":"10.1007","volume":"42","author":[{"given":"Sophie","family":"Ashley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananya","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hoskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YeePei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8878-7914","authenticated-orcid":false,"given":"Priyamvada","family":"Maitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,20]]},"reference":[{"key":"4744_CR1","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","volume":"38","author":"A Richters","year":"2020","unstructured":"Richters A, Aben KKH, Kiemeney LALM (2020) The global burden of urinary bladder cancer: an update. World J Urol 38:1895\u20131904. https:\/\/doi.org\/10.1007\/s00345-019-02984-4","journal-title":"World J Urol"},{"key":"4744_CR2","doi-asserted-by":"publisher","first-page":"834","DOI":"10.4143\/crt.2014.157","volume":"47","author":"H \u00d6zt\u00fcrk","year":"2015","unstructured":"\u00d6zt\u00fcrk H (2015) Detecting metastatic bladder cancer using 18F-fluorodeoxyglucose positron-emission tomography\/computed tomography. Cancer Res Treat 47:834\u2013843. https:\/\/doi.org\/10.4143\/crt.2014.157","journal-title":"Cancer Res Treat"},{"key":"4744_CR3","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/bju.14045","volume":"120","author":"Bladder cancer: diagnosis and management of bladder cancer: \u00a9 NICE","year":"2015","unstructured":"Bladder cancer: diagnosis and management of bladder cancer: \u00a9 NICE (2015) Bladder cancer: diagnosis and management of bladder cancer. BJU Int 120:755\u2013765. https:\/\/doi.org\/10.1111\/bju.14045","journal-title":"BJU Int"},{"key":"4744_CR4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/bju.15832","volume":"130","author":"I Jubber","year":"2022","unstructured":"Jubber I, Mitchell S, Hussain S et al (2022) Social deprivation and bladder cancer: cause or effect for disparities in survival for affected women. BJU Int 130:301\u2013302. https:\/\/doi.org\/10.1111\/bju.15832","journal-title":"BJU Int"},{"key":"4744_CR5","unstructured":"National Cancer Institute Bladder Cancer prognosis and Survival Rates. https:\/\/www.cancer.gov\/types\/bladder\/survival. Accessed 24 Apr 2023"},{"key":"4744_CR6","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H Von Der Maase","year":"2000","unstructured":"Von Der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. JCO 18:3068\u20133077. https:\/\/doi.org\/10.1200\/JCO.2000.18.17.3068","journal-title":"JCO"},{"key":"4744_CR7","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E et al (2020) Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 383:1218\u20131230. https:\/\/doi.org\/10.1056\/NEJMoa2002788","journal-title":"N Engl J Med"},{"key":"4744_CR8","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","volume":"22","author":"T Powles","year":"2021","unstructured":"Powles T, Cs\u0151szi T, \u00d6zg\u00fcro\u011flu M et al (2021) Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol 22:931\u2013945. https:\/\/doi.org\/10.1016\/S1470-2045(21)00152-2","journal-title":"Lancet Oncol"},{"key":"4744_CR9","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles T, Van Der Heijden MS, Castellano D et al (2020) Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 21:1574\u20131588. https:\/\/doi.org\/10.1016\/S1470-2045(20)30541-6","journal-title":"Lancet Oncol"},{"key":"4744_CR10","unstructured":"National Comprehensive Cancer Network Bladder Cancer Version 3.2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf"},{"key":"4744_CR11","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.ijrobp.2021.03.001","volume":"110","author":"YP Song","year":"2021","unstructured":"Song YP, Mistry H, Irlam J et al (2021) Long-term outcomes of radical radiation therapy with hypoxia modification with biomarker discovery for stratification: 10-year update of the BCON (bladder carbogen nicotinamide) phase 3 randomized trial (ISRCTN45938399). Int J Radiat Oncol Biol Phys 110:1407\u20131415. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.03.001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4744_CR12","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","volume":"24","author":"AR Zlotta","year":"2023","unstructured":"Zlotta AR, Ballas LK, Niemierko A et al (2023) Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol 24:669\u2013681. https:\/\/doi.org\/10.1016\/S1470-2045(23)00170-5","journal-title":"Lancet Oncol"},{"key":"4744_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00725","author":"M Swinton","year":"2023","unstructured":"Swinton M, Mariam NBG, Tan JL et al (2023) Bladder-sparing treatment with radical dose radiotherapy is an effective alternative to radical cystectomy in patients with clinically node-positive nonmetastatic bladder cancer. JCO. https:\/\/doi.org\/10.1200\/JCO.23.00725","journal-title":"JCO"},{"key":"4744_CR14","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0360-3016(00)00430-2","volume":"47","author":"GM Duchesne","year":"2000","unstructured":"Duchesne GM, Bolger JJ, Griffiths GO et al (2000) A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09. Int J Radiat Oncol Biol Phys 47:379\u2013388. https:\/\/doi.org\/10.1016\/S0360-3016(00)00430-2","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4744_CR15","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","volume":"21","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger M, Lievens Y, Bouma AB et al (2020) Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol 21:e18\u2013e28. https:\/\/doi.org\/10.1016\/S1470-2045(19)30718-1","journal-title":"Lancet Oncol"},{"key":"4744_CR16","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. The Lancet 392:2353\u20132366. https:\/\/doi.org\/10.1016\/S0140-6736(18)32486-3","journal-title":"The Lancet"},{"key":"4744_CR17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0167-8140(97)01943-9","volume":"43","author":"DB McLaren","year":"1997","unstructured":"McLaren DB, Morrey D, Mason MD (1997) Hypofractionated radiotherapy for muscle invasive bladder cancer in the elderly. Radiother Oncol 43:171\u2013174. https:\/\/doi.org\/10.1016\/S0167-8140(97)01943-9","journal-title":"Radiother Oncol"},{"key":"4744_CR18","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1053\/clon.1999.9075","volume":"11","author":"CC Jose","year":"1999","unstructured":"Jose CC, Price A, Norman A et al (1999) Hypofractionated radiotherapy for patients with carcinoma of the bladder. Clin Oncol 11:330\u2013333. https:\/\/doi.org\/10.1053\/clon.1999.9075","journal-title":"Clin Oncol"},{"key":"4744_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ijrobp.2017.01.239","volume":"98","author":"S Hafeez","year":"2017","unstructured":"Hafeez S, McDonald F, Lalondrelle S et al (2017) Clinical outcomes of image guided adaptive hypofractionated weekly radiation therapy for bladder cancer in patients unsuitable for radical treatment. Int J Radiat Oncol Biol Phys 98:115\u2013122. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.01.239","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4744_CR20","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ijrobp.2019.06.2541","volume":"105","author":"A Ali","year":"2019","unstructured":"Ali A, Song YP, Mehta S et al (2019) Palliative radiation therapy in bladder cancer\u2014importance of patient selection: a retrospective multicenter study. Int J Radiat Oncol Biol Phys 105:389\u2013393. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.06.2541","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4744_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00520-015-2765-y","volume":"24","author":"P Dirix","year":"2016","unstructured":"Dirix P, Vingerhoedt S, Joniau S et al (2016) Hypofractionated palliative radiotherapy for bladder cancer. Support Care Cancer 24:181\u2013186. https:\/\/doi.org\/10.1007\/s00520-015-2765-y","journal-title":"Support Care Cancer"},{"key":"4744_CR22","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.21873\/invivo.11718","volume":"33","author":"J Tey","year":"2019","unstructured":"Tey J, Soon YY, Cheo T et al (2019) Efficacy of palliative bladder radiotherapy for hematuria in advanced bladder cancer using contemporary radiotherapy techniques. In Vivo 33:2161\u20132167. https:\/\/doi.org\/10.21873\/invivo.11718","journal-title":"In Vivo"},{"key":"4744_CR23","doi-asserted-by":"publisher","first-page":"9533","DOI":"10.1038\/s41598-021-88952-8","volume":"11","author":"M Ogita","year":"2021","unstructured":"Ogita M, Kawamori J, Yamashita H, Nakagawa K (2021) Palliative radiotherapy for gross hematuria in patients with advanced cancer. Sci Rep 11:9533. https:\/\/doi.org\/10.1038\/s41598-021-88952-8","journal-title":"Sci Rep"},{"key":"4744_CR24","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S et al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393:2051\u20132058. https:\/\/doi.org\/10.1016\/S0140-6736(18)32487-5","journal-title":"Lancet"},{"key":"4744_CR25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ijrobp.2018.08.027","volume":"103","author":"P Sutera","year":"2019","unstructured":"Sutera P, Clump DA, Kalash R et al (2019) Initial results of a multicenter phase 2 trial of stereotactic ablative radiation therapy for oligometastatic cancer. Int J Radiat Oncol Biol Phys 103:116\u2013122. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.08.027","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4744_CR26","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S1470-2045(20)30537-4","volume":"22","author":"A Chalkidou","year":"2021","unstructured":"Chalkidou A, Macmillan T, Grzeda MT et al (2021) Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. Lancet Oncol 22:98\u2013106. https:\/\/doi.org\/10.1016\/S1470-2045(20)30537-4","journal-title":"Lancet Oncol"},{"key":"4744_CR27","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/iju.13773","volume":"25","author":"A Leonetti","year":"2018","unstructured":"Leonetti A, D\u2019Abbiero N, Baldari G et al (2018) Radiotherapy for the treatment of distant nodes metastases from oligometastatic urothelial cancer: a retrospective case series. Int J Urol 25:879\u2013886. https:\/\/doi.org\/10.1111\/iju.13773","journal-title":"Int J Urol"},{"key":"4744_CR28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.4149\/neo_2018_180522N333","volume":"66","author":"M Augugliaro","year":"2019","unstructured":"Augugliaro M, Marvaso G, Ciardo D et al (2019) Recurrent oligometastatic transitional cell bladder carcinoma: is there room for radiotherapy? Neo 66:160\u2013165. https:\/\/doi.org\/10.4149\/neo_2018_180522N333","journal-title":"Neo"},{"key":"4744_CR29","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3390\/cancers15041161","volume":"15","author":"A Aboudaram","year":"2023","unstructured":"Aboudaram A, Chaltiel L, Pouessel D et al (2023) Consolidative radiotherapy for metastatic urothelial bladder cancer patients with no progression and with no more than five residual metastatic lesions following first-line systemic therapy: a retrospective analysis. Cancers 15:1161. https:\/\/doi.org\/10.3390\/cancers15041161","journal-title":"Cancers"},{"key":"4744_CR30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.clon.2020.07.008","volume":"33","author":"C Franzese","year":"2021","unstructured":"Franzese C, Francolini G, Nicosia L et al (2021) Stereotactic body radiation therapy in the management of oligometastatic and oligoprogressive bladder cancer and other urothelial malignancies. Clin Oncol 33:50\u201356. https:\/\/doi.org\/10.1016\/j.clon.2020.07.008","journal-title":"Clin Oncol"},{"key":"4744_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2019.100124","volume":"19","author":"G Francolini","year":"2019","unstructured":"Francolini G, Desideri I, Detti B et al (2019) Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: a retrospective experience. Cancer Treat Res Commun 19:100124. https:\/\/doi.org\/10.1016\/j.ctarc.2019.100124","journal-title":"Cancer Treat Res Commun"},{"key":"4744_CR32","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.clgc.2017.04.007","volume":"15","author":"S Shah","year":"2017","unstructured":"Shah S, Zhang CA, Hancock S et al (2017) Consolidative radiotherapy in metastatic urothelial cancer. Clin Genitourin Cancer 15:685\u2013688. https:\/\/doi.org\/10.1016\/j.clgc.2017.04.007","journal-title":"Clin Genitourin Cancer"},{"key":"4744_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.05.005","author":"A Bamias","year":"2023","unstructured":"Bamias A, Stenzl A, Brown SL et al (2023) Definition and diagnosis of oligometastatic bladder cancer: a Delphi consensus study endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society Of Medical Oncology Genitourinary Faculty. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2023.05.005","journal-title":"Eur Urol"},{"key":"4744_CR34","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1186\/s12885-021-08861-x","volume":"21","author":"F Verghote","year":"2021","unstructured":"Verghote F, Poppe L, Verbeke S et al (2021) Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial. BMC Cancer 21:1113. https:\/\/doi.org\/10.1186\/s12885-021-08861-x","journal-title":"BMC Cancer"},{"key":"4744_CR35","doi-asserted-by":"publisher","first-page":"111819","DOI":"10.18632\/oncotarget.22911","volume":"8","author":"K Ogihara","year":"2017","unstructured":"Ogihara K, Kikuchi E, Watanabe K et al (2017) Can urologists introduce the concept of \u201coligometastasis\u201d for metastatic bladder cancer after total cystectomy? Oncotarget 8:111819\u2013111835. https:\/\/doi.org\/10.18632\/oncotarget.22911","journal-title":"Oncotarget"},{"key":"4744_CR36","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.ijrobp.2022.06.095","volume":"114","author":"JM Ryckman","year":"2022","unstructured":"Ryckman JM, Thomas TV, Wang M et al (2022) Local treatment of the primary tumor for patients with metastatic cancer (PRIME-TX): a meta-analysis. Int J Radiat Oncol Biol Phys 114:919\u2013935. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.06.095","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4744_CR37","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"LMS Boev\u00e9","year":"2019","unstructured":"Boev\u00e9 LMS, Hulshof MCCM, Vis AN et al (2019) Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol 75:410\u2013418. https:\/\/doi.org\/10.1016\/j.eururo.2018.09.008","journal-title":"Eur Urol"},{"key":"4744_CR38","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1001\/jamaoncol.2020.1808","volume":"6","author":"R You","year":"2020","unstructured":"You R, Liu Y-P, Huang P-Y et al (2020) Efficacy and safety of locoregional radiotherapy with chemotherapy vs chemotherapy alone in de novo metastatic nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical Trial. JAMA Oncol 6:1345. https:\/\/doi.org\/10.1001\/jamaoncol.2020.1808","journal-title":"JAMA Oncol"},{"key":"4744_CR39","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1200\/JCO.2016.66.7352","volume":"34","author":"T Seisen","year":"2016","unstructured":"Seisen T, Sun M, Leow JJ, et al (2016) Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score\u2013Weighted Analysis From the National Cancer Data Base. J Clin Oncol 34:3529\u20133536. https:\/\/doi.org\/10.1200\/JCO.2016.66.7352","journal-title":"J Clin Oncol"},{"key":"4744_CR40","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.euo.2022.02.001","volume":"5","author":"BW Fischer-Valuck","year":"2022","unstructured":"Fischer-Valuck BW, Patel SA, Brenneman RJ et al (2022) Association between local radiation therapy to the primary bladder tumor and overall survival for patients with metastatic urothelial cancer receiving systemic chemotherapy. Eur Urol Oncol 5:246\u2013250. https:\/\/doi.org\/10.1016\/j.euo.2022.02.001","journal-title":"Eur Urol Oncol"},{"key":"4744_CR41","first-page":"3009","volume":"13","author":"K Passaperuma","year":"2006","unstructured":"Passaperuma K, Ash R, Venkatesan V et al (2006) Pelvic chemoradiotherapy after chemotherapy for metastatic bladder cancer. Can J Urol 13:3009\u20133015","journal-title":"Can J Urol"},{"key":"4744_CR42","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1097\/01.ju.0000067601.29966.4a","volume":"169","author":"P Sweeney","year":"2003","unstructured":"Sweeney P, Millikan R, Donat M et al (2003) Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol 169:2113\u20132117. https:\/\/doi.org\/10.1097\/01.ju.0000067601.29966.4a","journal-title":"J Urol"},{"key":"4744_CR43","doi-asserted-by":"publisher","first-page":"59.e1","DOI":"10.1016\/j.urolonc.2015.08.012","volume":"34","author":"PL Ho","year":"2016","unstructured":"Ho PL, Willis DL, Patil J et al (2016) Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: the M.D. Anderson Cancer Center Experience. Urol Oncol: Semin Origin Investig 34:59.e1-59.e8. https:\/\/doi.org\/10.1016\/j.urolonc.2015.08.012","journal-title":"Urol Oncol: Semin Origin Investig"},{"key":"4744_CR44","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.purol.2013.03.004","volume":"23","author":"Y Neuzillet","year":"2013","unstructured":"Neuzillet Y, Larr\u00e9 S, Comperat E et al (2013) Traitement chirurgical du carcinome uroth\u00e9lial de vessie m\u00e9tastatique\u202f: revue du Comit\u00e9 de canc\u00e9rologie de l\u2019Association fran\u00e7aise d\u2019urologie. Prog Urol 23:951\u2013957. https:\/\/doi.org\/10.1016\/j.purol.2013.03.004","journal-title":"Prog Urol"},{"key":"4744_CR45","unstructured":"National Comprehensive Cancer Network NCCN Bladder Cancer Version2.2021"},{"key":"4744_CR46","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s00345-020-03440-4","volume":"39","author":"M Daro-Faye","year":"2021","unstructured":"Daro-Faye M, Kassouf W, Souhami L et al (2021) Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response. World J Urol 39:1331\u20131343. https:\/\/doi.org\/10.1007\/s00345-020-03440-4","journal-title":"World J Urol"},{"key":"4744_CR47","doi-asserted-by":"publisher","first-page":"19740","DOI":"10.1038\/srep19740","volume":"6","author":"C-T Wu","year":"2016","unstructured":"Wu C-T, Chen W-C, Chang Y-H et al (2016) The role of PD-L1 in the radiation response and clinical outcome for bladder cancer. Sci Rep 6:19740. https:\/\/doi.org\/10.1038\/srep19740","journal-title":"Sci Rep"},{"key":"4744_CR48","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.eururo.2019.01.009","volume":"75","author":"N Sundahl","year":"2019","unstructured":"Sundahl N, Vandekerkhove G, Decaestecker K et al (2019) Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma. Eur Urol 75:707\u2013711. https:\/\/doi.org\/10.1016\/j.eururo.2019.01.009","journal-title":"Eur Urol"},{"key":"4744_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.02.018","author":"P Maitre","year":"2023","unstructured":"Maitre P, Sangar V, Choudhury A (2023) ADAPT and improvise: overcoming Bacillus Calmette-Gu\u00e9rin unresponsiveness in non\u2013muscle-invasive bladder cancer. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2023.02.018","journal-title":"Eur Urol"},{"key":"4744_CR50","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.ijrobp.2018.04.070","volume":"101","author":"AC Tree","year":"2018","unstructured":"Tree AC, Jones K, Hafeez S et al (2018) Dose-limiting urinary toxicity with pembrolizumab combined with weekly hypofractionated radiation therapy in bladder cancer. Int J Radiat Oncol Biol Phys 101:1168\u20131171. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.04.070","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4744_CR51","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.eururo.2023.01.017","volume":"83","author":"NM Hahn","year":"2023","unstructured":"Hahn NM, O\u2019Donnell MA, Efstathiou JA et al (2023) A phase 1 trial of durvalumab in combination with Bacillus Calmette-Guerin (BCG) or external beam radiation therapy in patients with BCG-unresponsive non-muscle-invasive bladder cancer: the hoosier cancer research network GU16-243 ADAPT-BLADDER study. Eur Urol 83:486\u2013494. https:\/\/doi.org\/10.1016\/j.eururo.2023.01.017","journal-title":"Eur Urol"},{"key":"4744_CR52","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41467-020-20493-6","volume":"12","author":"G Vandekerkhove","year":"2021","unstructured":"Vandekerkhove G, Lavoie J-M, Annala M et al (2021) Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nat Commun 12:184. https:\/\/doi.org\/10.1038\/s41467-020-20493-6","journal-title":"Nat Commun"},{"key":"4744_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111859","volume":"41","author":"TN Clinton","year":"2022","unstructured":"Clinton TN, Chen Z, Wise H et al (2022) Genomic heterogeneity as a barrier to precision oncology in urothelial cancer. Cell Rep 41:111859. https:\/\/doi.org\/10.1016\/j.celrep.2022.111859","journal-title":"Cell Rep"},{"key":"4744_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007613","volume":"11","author":"J Anker","year":"2023","unstructured":"Anker J, Pal SK, Kim-Schulze S et al (2023) Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer. J Immunother Cancer 11:e007613. https:\/\/doi.org\/10.1136\/jitc-2023-007613","journal-title":"J Immunother Cancer"},{"key":"4744_CR55","unstructured":"Stereotactic body radiotherapy in addition to standard of care treatment in patients with rare oligometastatic cancers (OligoRARE): a randomized, phase 3, open-label trial. https:\/\/clinicaltrials.gov\/study\/NCT04498767. Accessed 16 Oct 2023"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-023-04744-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-023-04744-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-023-04744-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:19:11Z","timestamp":1735852751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-023-04744-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,20]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4744"],"URL":"https:\/\/doi.org\/10.1007\/s00345-023-04744-x","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,20]]},"assertion":[{"value":"12 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.C is the Editor-in-chief of BMJ Oncology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is an observational review and does not involve human or animal participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"This review does not involve individual participant data, and therefore, consent is not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"47"}}